Endocrinological late effects after chemotherapy for testicular cancer

British Journal of Cancer

Volumn 73, Issue 9, 1996, Pages 1108-1114

  Berger, C C ^a   Bokemeyer, C ^a,b   Schuppert, F ^a   Schmoll, H J ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Chemotherapy; Endocrinological sequelae; Long term toxicity; Testicular cancer

Indexed keywords

BLEOMYCIN; ESTRONE; ETOPOSIDE; FOLLITROPIN; GONADOTROPIN; HYDROXYPROGESTERONE; LUTEINIZING HORMONE; PLATINUM; PRASTERONE; TESTOSTERONE; VINBLASTINE;

ADULT; ARTICLE; CHEMOTHERAPY; CHOLESTEROL BLOOD LEVEL; DRUG POTENTIATION; FOLLITROPIN BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; TESTIS CANCER;

EID: 0029876301     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.213     Document Type: Article

References (47)

1. AASS N, KAASA S, LUND E, KAALHUS O, SKARD HEITER M AND FOSSA SD. (1990). Long-term somatic side-effects and morbility in testicular cancer patients. Br. J. Cancer. 61, 151-155.
2. AKSOY IA, SOCHOROVA V AND WEINSHILBOUM RM. (1993). Human liver dehydroepiandosterone sulphotransferase: nature and extent of individual variation. Clin. Pharmacol. Ther., 54, 498-506.
3. ASSMANN G AND SCHULTE H. (1986). PROCAM Studie. Panscientia: Zurich.
4. BAIN JR, LANGERIN M, D'COSTA R, SANDS M AND HUCHER S. (1988). Serum-pituitary and steroid hormone levels in the adult male: one value is as good as three. Fertil. Steril., 49, 123-126.
5. BARRETT-CONNOR E AND KHAW K-T. (1988). Endogenous sex hormones and cardiovascular disease in men. Circulation. 8, 539-545.
6. BARRETT-CONNOR E, KHAW K-T AND YEN SSC. (1986). A prospective study of DHEAS, mortality, and cardiovascular disease. N. Engl. J. Med., 315, 1519-1524.
7. BERGER CC, BOKEMEYER C, SCHNEIDER M, KUCZYK MA AND SCHMOLL H-J. (1995). Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur. J. Cancer, 31 A, 2229-2238.
8. BISSETT D, KUNKELER L, ZWANENBURG L, PAUL J, GRAY C, SWAN IRC, KERR DJ AND KAYE SB. (1990). Long-term sequelae of treatment for testicular germ cell tumour. Br. J. Cancer, 62, 655-659.
9. BLACKMAN MR, WEINTRAUB BD, ROSEN SW AND HARMANN SM. (1988). Comparison of the effects of lung cancer, benign lung disease, and normal aging on pituitary - gonadal function in men. J. Clin. Endocrinol. Metab., 66, 88-95.
10. BOKEMEYER C, BERGER CC, KYNAST B, SCHMOLLL H-J AND POLIWODA H. (1993). Ototoxicity following therapy for testicular cancer. Eur. J. Cancer, 29A, (suppl. 6), 1357.
11. BOKEMEYER C, SCHMOLL H-J, VON RHEE J, KUCZYK M, SCHUPPERT F AND POLIWODA H. (1994). Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma. Ann Hematol., 68, 105-110.
12. BOSL GJ AND BAJORUNAS D. (1987). Pituitary and testicular hormonal function after treatment for germ cell tumour. Int. J. Androl., 10, 381-384.
13. BOYER M, RAGHAVAN D, HARRIS PJ, LIETCH J, BLEASEL A, WALSH JC, ANDERSON S AND TSANO C-S. (1990). Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy lor metastatic testicular cancer. J. Clin. Oncol., 8, 21-26.
14. CAMPOS JL. (1972). Continuous positive aging in Hodgkin's disease. Br. J. Radiol., 45, 917-922.
15. CARROLL PR, WHITMORE JR W, HERR H, MORSE M, SOGANI P, BAJORUNAS D, FAIR WR AND CHAGANTI RSK. (1987). Endocrine and exocrine profiles of men with testicular tumours before orchidectomy. J. Urol., 137, 420-423.
16. COCHRAN JS, WALSH PC, PORTER JC, NICHOLSON TC, MADDEN JD AND PETERS DC. (1975). The endocrinology of human chorion gonadotropin-secreting testicular tumours: a new method in diagnosis. J. Urol., 114, 549.
17. DRASGA RE, EINHORN LH, WILLIAMS SD, PATEL DN AND STEVENS EE. (1983). Fertility after chemotherapy for testicular cancer. J. Clin. Oncol., 1, 179-183.
18. EINHORN LA AND DONOHUE J. (1977). Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann. Intern. Med., 87, 293-298.
19. ELLIS PA, GEORGE PM, ROBINSON BA, ATKINSON CH AND COLLS BM. (1992). Fasting plasma lipid measurements following cisplatin chemotherapy in patients with germ cell tumours. J. Clin. Oncol., 10, 1609-1614.
20. FOSSA SD, OUS S, ABYHOLM T, NORMAN N AND LOEB M. (1985). Post-treatment fertility in patients with testicular cancer. (II). Br. J. Urol., 57, 210-214.
21. GIETEMA JA, SLEIJFER DTH, WILLEMSE PHB AND SCHRAFFORDT KOOPS H (1992). Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann. Intern. Med., 116, 709-715.
22. GIONA F, ANNINO L, DONATO P AND ERMINI M. (1994). Gonadal, adrenal, androgen and thyroid functions in adults treated for acute lymphoblastic leukemia. Haematologica., 79, 141-147.
23. HAFFNER SM, MYKKANEN L, VALDEZ RA AND KATZ MS. (1993). Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J. Clin. Endocrinol. Metab., 77, 1610-1615.
24. HANSEN SW, BERTHELSEN JG AND VON DER MAASE H. (1990). Long-term fertility and leydig cell function in patients treated for germ cell cancer with cisplatin, vinblastine, and bleomycin versus surveillance. J. Clin. Oncol., 8, 1695-1698.
25. HENDRY WF, STEDRONSKA J, JONES CR, BLACKMORE CA, BARRETT A AND PECKHAM MJ. (1983). Semen analysis in testicular cancer and Hodgkin's disease: pre- and post-treatment findings and implications for cryopreservation. Br. J. Urol., 55, 769-773.
26. HOEPPNER W, REINEL D AND HARTMANN M. (1986). Untersuchungen zur Fertilitaet von Patienten mit malignen Hodentumoren zum Zeitpunkt der Orchidektomie. Andrologica, 18, 398-405.
27. HOLMES SJ, WHITEHOUSH RW, CLARK ST, CROWTHER DC, ADAMS JH AND SHALET SM. (1994). Reduced bone mineral density in men following chemotherapy for Hodgkin's disease. Br. J. Cancer, 70, 371-375.
28. HORTON RJ. (1990). Testicular steroid transport, metabolism and effects. In Principles and Practice of Endocrinology and Metabolism. Becker KL (ed.) pp.937 941. Lippincott: Philadelphia.
29. HORWICH A, LAMPE H, NORMAN A, NICHOLLS J, JAY G AND DEARNALEY D. (1995). Fertility after chemotherapy for metastatic germ cell tumours. Proc. ASCO., 14, 235.
30. JACOBS DR, MEBANE IL, BANGDIWALA SI, CRIQUI MH AND TYROLER HA. (1990). High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am. J. Epidemiol., 31, 32-47.
31. KRAUSE W AND PFLUEGER KH. (1989). Treatment with gonadotropin-releasing-hormone agonist buserelin to protect spermatogenesis against cytotoxic treatment in young men. Andrologia, 21, 265-270.
32. KREUSER ED, KURRLE E, HETZEL WD, HETMER B, PORZSOLT F, HAUTMANN R, GAUS W, SCHLIPF U, PFEIFFER EF AND HEIMPEL H. (1989). Reversible Keimzelltoxizität nach aggressiver Chemotherapie bei Patienten mit Hodentumoren: Ergebnisse einer prospektiven Studie. Klin. Wochenschr., 67, 367-378.
33. LEBLANC GA, KANTOFF PW, FREI E AND WAXMAN DJ. (1992). Hormonal perturbations in patients with testicular cancer treated with cisplatin. Cancer, 69, 2306-2310.
34. LEITNER SP, BOSL GJ AND BAJORUNAS D. (1986). Gonadal dysfunction in patients treated for metastatic germ cell tumour. J. Clin. Oncol., 4, 1500-1505.
35. LIU CH, LAUGHLIN GA, FISCHER UG AND YEN SS. (1990). Marked attenuation of ultradian and circadian rhthyms of dehydroepiandrosterone in postmenopausal women: evidence for a reduced 17, 20-desmolase enzymatic activity. J. Clin. Endocrinol. Metab., 71, 900-906.
36. scc in rat testis. Endocrinology, 126, 2398 2406.
37. MANCINI RE, LAVIERI JC, MULLER F, ANDRADA HA AND SARACENI DJ. (1966). Effect of prednisolone upon normal and pathologic human spermatogenesis. Fertil. Steril., 17, 500.
38. NEIL HAW, MANT D, JONES L, MORGAN B AND MANN JI. (1990). Lipid screening: is it enough to measure total cholesterol concentration? Br. Med. J., 301, 584-587.
39. ORENTREICH N, BRIND JL, RIZER RL AND VOGELMAN JH. (1984). Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J. Clin. Endocrinol. Metab., 59, 551-555.
40. PARKER LN. (1995). Adrenal Androgens. In Endocrinology, De Groot LJ. (ed.) pp. 1836-1851. W.B. Saunders: Philadelphia.
41. PASQUALI R, CASIMIRRI F, CANTOBELLI S, MELCHIONDA N, LABATE AMM, FABBRI R, CAPELLI M AND BORTOLUZZI L. (1991). Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism, 40, 101-104.
42. RAGHAVAN D, COX K, CHILDS A, GRYGIEL J AND SULLIVAN D. (1992). Hypercholesterolemia after chemotherapy for testis cancer. J. Clin. Oncol., 10, 1386-1389.
43. REGELSON W, LORIA R AND KALIMI M. (1994). Dehydroepiandrosterone (DHEA) - the 'mother steroid. Ann. N. Y. Acad. Sci., 719, 553-563.
44. ROTH BJ, GRIEST A, KUBILIS PS, WILLIAMS SD AND EINHORN LH. (1988). Cisplatin-based combination chemotherapy for disseminated gem cell tumour: long-term follow-up. J. Clin. Oncol., 6, 1239-1247.
45. SCHWABE H-R, HERRMANN R, MATHEW M, GRAEF K-J, SANDER T, CORDES M, NAGEL R, WEISSBACH L AND HUHN D. (1992). Langfristige Toxizitaet der Polychemotherapie bei kurativ behandeltem Hodenkarzinom. Dtsch. Med. Wschr., 117, 121-126.
46. SPITZ S. (1948). The histological effects of nitrogen mustards on human tumours and tissues. Cancer, 1, 383.
47. ZUMOFE B, ROSENFELD RS, STRAIN GW, LEVIN J AND FUKUSHIMA DK. (1980). Sex differences in the 24-hour mean plasma concentrations of dehydroisoandrosterone (DHA) and dehydroisoandrosterone sulfate (DHS) and the DHA to DHS ratio in normal adults. J. Clin. Endocrinol. Metab., 51, 330-333.